Patents Assigned to Gloriana Therapeutics
-
Publication number: 20220048984Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: ApplicationFiled: December 20, 2019Publication date: February 17, 2022Applicant: GLORIANA THERAPEUTICS SARLInventors: Alan Gilbert, Kyle Mcelearney, Terrance Michael Dobrowsky, Rashmi Riohit Kshirsagar
-
Patent number: 10888526Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: December 22, 2017Date of Patent: January 12, 2021Assignee: GLORIANA THERAPEUTICS SARLInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Patent number: 10835664Abstract: The invention comprises an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.Type: GrantFiled: April 30, 2017Date of Patent: November 17, 2020Assignee: Gloriana TherapeuticsInventors: Lars Ulrik Wahlberg, Jens Tornøe
-
Patent number: 10717965Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: GrantFiled: December 21, 2018Date of Patent: July 21, 2020Assignee: Gloriana Therapeutics, Inc.Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Patent number: 10669523Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: GrantFiled: December 21, 2018Date of Patent: June 2, 2020Assignee: Gloriana Therapeutics, Inc.Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Patent number: 10328125Abstract: Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide.Type: GrantFiled: February 27, 2007Date of Patent: June 25, 2019Assignee: GLORIANA THERAPEUTICS, INC.Inventors: Anthony Rossomando, Frank Porreca, Dinah Wen-Yee Sah
-
Patent number: 10047150Abstract: Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.Type: GrantFiled: January 5, 2015Date of Patent: August 14, 2018Assignee: GLORIANA THERAPEUTICS SARLInventors: Anthony Rossomando, Ping Jin
-
Patent number: 9884023Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: August 7, 2015Date of Patent: February 6, 2018Assignee: Gloriana Therapeutics sarlInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20170232186Abstract: The invention features an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.Type: ApplicationFiled: April 30, 2017Publication date: August 17, 2017Applicant: Gloriana Therapeutics sarlInventors: Lars Ulrik Wahlberg, Jens Tornøe
-
Patent number: 9669154Abstract: The invention features an implantable cell device. The device includes a membrane defining and enclosing a chamber; a distance body, within the chamber, for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold, within the chamber, for increasing the cell support surface area per unit volume of the chamber for distributing cells.Type: GrantFiled: September 27, 2011Date of Patent: June 6, 2017Assignee: Gloriana Therapeutics, sarlInventors: Lars Ulrik Wahlberg, Jens Tornøe
